Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

3(37.5%)

Phase 2

2(25.0%)

Phase 4

2(25.0%)

Phase 3

1(12.5%)

8Total

Phase 1(3)

Phase 2(2)

Phase 4(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07213765Phase 4Recruiting

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

Role: collaborator

NCT07084402Phase 4Recruiting

Short-term Bactericidal Effect of Contezolid in MAC-PD

Role: collaborator

NCT05369052Phase 3Recruiting

Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)

Role: lead

NCT02269319Phase 2Completed

MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

Role: lead

NCT03033342Phase 1Completed

Single Dose and Multiple Dose Escalation Trial of an Oral Formulation of MRX-4

Role: lead

NCT04649541Phase 1Completed

Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts

Role: lead

NCT03747497Phase 2Completed

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

Role: lead

NCT03033329Phase 1Completed

Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4

Role: lead

All 8 trials loaded